Inventor · disambiguated record
Christian Klein
Also filed as: KLEIN CHRISTIAN
171 granted patents·273 pending applications·2,450 citations·filing 1986–2025
99Inventor score
Files withHOFFMANN LA ROCHE255ROCHE GLYCART AG70BOEHRINGER MANNHEIM GMBH20GENENTECH INC14BRINKMANN ULRICH9
Top patents by PatentIndex Score
444 records- 0198US11130822B2ImmunoconjugatesROCHE GLYCART AG·Filed 2019·Granted Sep 28, 2021·16 cites·24 claims
- 0298US10316104B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Jun 11, 2019·30 cites·23 claims
- 0398US10202464B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Feb 12, 2019·30 cites·3 claims
- 0498US10184009B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2017·Granted Jan 22, 2019·37 cites·30 claims
- 0598US9447159B2ImmunoconjugatesAST OLIVER·Filed 2012·Granted Sep 20, 2016·111 cites·27 claims
- 0698US8242247B2Bivalent, bispecific antibodiesKLEIN CHRISTIAN·Filed 2008·Granted Aug 14, 2012·110 cites·13 claims
- 0798US8227577B2Bivalent, bispecific antibodiesKLEIN CHRISTIAN·Filed 2008·Granted Jul 24, 2012·148 cites·5 claims
- 0897US11673945B2Bispecific antigen binding proteinsHOFFMANN LA ROCHE·Filed 2020·Granted Jun 13, 2023·4 cites·9 claims
- 0997US11306154B2Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Apr 19, 2022·13 cites·56 claims
- 1097US11267903B2Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Mar 8, 2022·17 cites·46 claims
- 1197US10577429B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Mar 3, 2020·17 cites·28 claims
- 1297US10464981B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Nov 5, 2019·33 cites·22 claims
- 1397US10323098B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2016·Granted Jun 18, 2019·25 cites·30 claims
- 1497US10253110B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Apr 9, 2019·15 cites·17 claims
- 1597US9695233B2Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2013·Granted Jul 4, 2017·44 cites·11 claims
- 1697US9382323B2Multispecific antibodies comprising full length antibodies and single chain fab fragmentsBRINKMANN ULRICH·Filed 2010·Granted Jul 5, 2016·77 cites·22 claims
- 1797US9266938B2Mutant interleukin-2 polypeptidesAST OLIVER·Filed 2012·Granted Feb 23, 2016·123 cites·25 claims
- 1897US8268314B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2009·Granted Sep 18, 2012·70 cites·18 claims
- 1996US11718680B2Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonistsHOFFMANN LA ROCHE·Filed 2020·Granted Aug 8, 2023·5 cites·32 claims
- 2096US11447558B2Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9HOFFMANN LA ROCHE·Filed 2019·Granted Sep 20, 2022·14 cites·22 claims
- 2196US11111312B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2018·Granted Sep 7, 2021·8 cites·5 claims
- 2296US10392445B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Aug 27, 2019·31 cites·39 claims
- 2396US9539251B2Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitorGENENTECH INC·Filed 2013·Granted Jan 10, 2017·24 cites·14 claims
- 2496US9526797B2Combination IL-2 immunoconjugate therapyROCHE GLYCART AG·Filed 2013·Granted Dec 27, 2016·57 cites·20 claims
- 2596US9080183B2PromoterKLEIN CHRISTIAN·Filed 2008·Granted Jul 14, 2015·38 cites·9 claims
- 2695US11780920B2Antibodies binding to CD3 and CD19HOFFMANN LA ROCHE·Filed 2021·Granted Oct 10, 2023·4 cites·59 claims
- 2795US11149083B2Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moietyHOFFMANN—LA ROCHE INC·Filed 2018·Granted Oct 19, 2021·12 cites·25 claims
- 2895US11110087B2Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitorGENENTECH INC·Filed 2021·Granted Sep 7, 2021·5 cites·29 claims
- 2995US10941205B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 9, 2021·10 cites·13 claims
- 3095US10526413B2Bispecific antibodies specific for OX40HOFFMANN LA ROCHE·Filed 2016·Granted Jan 7, 2020·23 cites·20 claims
- 3195US9266967B2Bivalent, bispecific antibodiesKLEIN CHRISTIAN·Filed 2008·Granted Feb 23, 2016·30 cites·15 claims
- 3295US8703132B2Bispecific, tetravalent antigen binding proteinsIMHOF-JUNG SABINE·Filed 2010·Granted Apr 22, 2014·64 cites·11 claims
- 3395US8133979B2Antibodies against human angiopoietin 2BRINKMANN ULRICH·Filed 2009·Granted Mar 13, 2012·19 cites·10 claims
- 3494US11590128B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2022·Granted Feb 28, 2023·3 cites·7 claims
- 3594US11413282B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2016·Granted Aug 16, 2022·4 cites·10 claims
- 3694US11332545B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2019·Granted May 17, 2022·6 cites·9 claims
- 3794US10683369B2Monoclonal antibodies against BCMAENGMAB SARL·Filed 2016·Granted Jun 16, 2020·14 cites·21 claims
- 3894US9914776B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2015·Granted Mar 13, 2018·16 cites·42 claims
- 3994US9890204B2Trivalent, bispecific antibodiesBRINKMANN ULRICH·Filed 2012·Granted Feb 13, 2018·27 cites·11 claims
- 4094US9011847B2Anti-FAP antibodies and methods of useBACAC MARINA·Filed 2011·Granted Apr 21, 2015·34 cites·26 claims
- 4194US8945552B2Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2011·Granted Feb 3, 2015·36 cites·12 claims
- 4294US8796424B2Tri- or tetraspecific antibodiesCROASDALE REBECCA·Filed 2010·Granted Aug 5, 2014·59 cites·26 claims
- 4394US8703130B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2012·Granted Apr 22, 2014·23 cites·12 claims
- 4494US4954630AResorufin derivativesBOEHRINGER MANNHEIM GMBH·Filed 1986·Granted Sep 4, 1990·42 cites·9 claims
- 4593US11285207B2Bispecific antibodies specifically binding to PD1 and LAG3HOFFMANN LA ROCHE·Filed 2018·Granted Mar 29, 2022·10 cites·32 claims
- 4693US11242396B2Bispecific antigen binding molecules comprising anti-FAP clone 212HOFFMANN LA ROCHE·Filed 2019·Granted Feb 8, 2022·14 cites·36 claims
- 4793US10993942B2Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitorGENENTECH INC·Filed 2020·Granted May 4, 2021·3 cites·30 claims
- 4893US10781258B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·4 cites·39 claims
- 4993US10603360B2Combination IL-2 immunoconjugate therapyROCHE GLYCART AG·Filed 2016·Granted Mar 31, 2020·13 cites·22 claims
- 5093US10155815B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2014·Granted Dec 18, 2018·12 cites·46 claims
Showing the top 50 of 444 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Christian Klein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →